Bilcare Ltd
Incorporated in 1987, Bilcare Ltd. is engaged in the business of Pharmaceutical Packaging, Global Clinical Services, R&D services and Anti Counterfeit Technology (nCid).
- Market Cap ₹ 130 Cr.
- Current Price ₹ 55.2
- High / Low ₹ 95.4 / 51.0
- Stock P/E
- Book Value ₹ 176
- Dividend Yield 0.00 %
- ROCE -1.97 %
- ROE -2.61 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Stock is trading at 0.31 times its book value
- Debtor days have improved from 142 to 101 days.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -40.7% over past five years.
- Promoter holding is low: 30.0%
- Company has a low return on equity of -10.2% over last 3 years.
- Contingent liabilities of Rs.709 Cr.
- Company's cost of borrowing seems high
- Working capital days have increased from 165 days to 1,139 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
727.43 | 401.35 | 331.33 | 315.42 | 285.60 | 257.53 | 239.81 | 211.75 | 304.16 | 429.79 | 13.98 | 17.60 | 16.98 | |
544.09 | 336.96 | 310.30 | 300.30 | 288.45 | 257.77 | 238.89 | 219.34 | 279.00 | 393.05 | 21.12 | 26.71 | 26.17 | |
Operating Profit | 183.34 | 64.39 | 21.03 | 15.12 | -2.85 | -0.24 | 0.92 | -7.59 | 25.16 | 36.74 | -7.14 | -9.11 | -9.19 |
OPM % | 25.20% | 16.04% | 6.35% | 4.79% | -1.00% | -0.09% | 0.38% | -3.58% | 8.27% | 8.55% | -51.07% | -51.76% | -54.12% |
-27.33 | 30.35 | 4.36 | -105.57 | 73.52 | 259.53 | 5.59 | 38.18 | 66.58 | 42.55 | 515.03 | 19.45 | 13.18 | |
Interest | 102.49 | 147.04 | 131.84 | 31.73 | 47.82 | 55.53 | 72.10 | 69.08 | 74.72 | 68.19 | 0.45 | 2.49 | 5.92 |
Depreciation | 42.00 | 67.81 | 105.52 | 101.29 | 79.23 | 304.34 | 248.47 | 88.06 | 34.63 | 34.64 | 4.52 | 2.15 | 2.69 |
Profit before tax | 11.52 | -120.11 | -211.97 | -223.47 | -56.38 | -100.58 | -314.06 | -126.55 | -17.61 | -23.54 | 502.92 | 5.70 | -4.62 |
Tax % | 42.97% | 1.12% | -13.35% | -65.00% | 16.94% | -20.52% | 0.38% | -19.15% | -110.11% | -24.47% | 22.30% | 6.32% | |
6.58 | -121.46 | -183.68 | -78.22 | -65.93 | -79.94 | -315.25 | -102.32 | 1.78 | -17.78 | 390.79 | 5.34 | -5.21 | |
EPS in Rs | 2.79 | -51.59 | -78.01 | -33.22 | -28.00 | -33.95 | -133.89 | -43.46 | 0.76 | -7.55 | 165.97 | 2.27 | -2.22 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | -27% |
5 Years: | -41% |
3 Years: | -61% |
TTM: | 5% |
Compounded Profit Growth | |
---|---|
10 Years: | 7% |
5 Years: | 14% |
3 Years: | 22% |
TTM: | -145% |
Stock Price CAGR | |
---|---|
10 Years: | 0% |
5 Years: | 21% |
3 Years: | -12% |
1 Year: | -23% |
Return on Equity | |
---|---|
10 Years: | -31% |
5 Years: | -29% |
3 Years: | -10% |
Last Year: | -3% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 23.55 | 23.55 | 23.55 | 23.55 | 23.55 | 23.55 | 23.55 | 23.55 | 23.55 | 23.55 | 23.55 | 23.55 | 23.55 |
Reserves | 944.46 | 831.24 | 643.47 | 598.97 | 532.92 | 453.08 | 137.88 | 35.63 | 37.17 | 19.86 | 386.86 | 392.11 | 390.96 |
1,380.93 | 1,227.93 | 1,151.44 | 975.70 | 898.21 | 856.59 | 867.63 | 708.56 | 678.41 | 689.92 | 7.52 | 10.29 | 10.83 | |
338.00 | 553.54 | 802.28 | 441.11 | 517.98 | 284.84 | 346.08 | 204.85 | 189.19 | 193.25 | 41.89 | 34.54 | 32.56 | |
Total Liabilities | 2,686.94 | 2,636.26 | 2,620.74 | 2,039.33 | 1,972.66 | 1,618.06 | 1,375.14 | 972.59 | 928.32 | 926.58 | 459.82 | 460.49 | 457.90 |
636.67 | 1,254.77 | 1,217.32 | 1,176.79 | 1,147.47 | 843.72 | 593.73 | 506.21 | 472.60 | 445.82 | 16.25 | 63.41 | 62.33 | |
CWIP | 785.13 | 181.61 | 124.66 | 0.00 | 0.00 | 0.25 | 0.28 | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 694.37 | 683.13 | 682.43 | 552.73 | 552.88 | 514.03 | 513.37 | 173.17 | 89.49 | 80.51 | 293.51 | 293.52 | 294.53 |
570.77 | 516.75 | 596.33 | 309.81 | 272.31 | 260.06 | 267.76 | 293.21 | 366.15 | 400.25 | 150.06 | 103.56 | 101.04 | |
Total Assets | 2,686.94 | 2,636.26 | 2,620.74 | 2,039.33 | 1,972.66 | 1,618.06 | 1,375.14 | 972.59 | 928.32 | 926.58 | 459.82 | 460.49 | 457.90 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
143.51 | 177.21 | -16.68 | 28.44 | 37.28 | 7.17 | 62.13 | 71.12 | -0.41 | 46.29 | 397.43 | 97.63 | |
-864.58 | -31.09 | -14.39 | 8.62 | -48.08 | 78.31 | 1.51 | 10.82 | 85.02 | 5.59 | 180.97 | -107.06 | |
726.49 | -153.00 | 22.55 | -35.07 | 6.24 | -86.70 | -60.25 | -83.03 | -82.28 | -55.47 | -570.94 | -0.51 | |
Net Cash Flow | 5.42 | -6.88 | -8.51 | 1.98 | -4.56 | -1.22 | 3.39 | -1.08 | 2.33 | -3.59 | 7.47 | -9.94 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 50.89 | 95.28 | 79.96 | 69.13 | 62.11 | 57.94 | 56.41 | 67.40 | 86.74 | 78.67 | 246.73 | 101.41 |
Inventory Days | 106.70 | 152.84 | 214.55 | 85.46 | 50.98 | 50.90 | 68.40 | 56.55 | 85.32 | 71.21 | 60.10 | 21.27 |
Days Payable | 158.89 | 165.49 | 180.64 | 77.49 | 86.11 | 114.26 | 155.62 | 128.77 | 116.24 | 100.16 | 439.03 | 91.35 |
Cash Conversion Cycle | -1.30 | 82.62 | 113.87 | 77.11 | 26.99 | -5.42 | -30.82 | -4.82 | 55.82 | 49.72 | -132.20 | 31.33 |
Working Capital Days | 130.14 | -12.29 | -104.94 | -225.39 | -320.99 | -75.32 | -162.55 | -98.37 | -0.18 | -4.43 | -638.36 | 1,138.76 |
ROCE % | 7.11% | -0.46% | -4.11% | -4.38% | -5.02% | -20.87% | -20.40% | -9.08% | 0.34% | 1.51% | -1.38% | -1.97% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
14 Nov - Newspaper Publication of Unaudited Financial Results (Standalone and Consolidated) for the Quarter and Half Year ended 30th September 2024
-
Unaudited Financial Results (Standalone And Consolidated) For The Quarter & Half Year Ended 30Th September 2024
13 Nov - Bilcare Limited approved unaudited financial results for Q2 2024.
-
Board Meeting Outcome for Board Meeting Outcome For Unaudited Financial Results (Standalone And Consolidated) For The Quarter & Half Year Ended 30Th September 2024 Together With The Limited Review Report Of The Statutory Auditor Thereon.
13 Nov - Bilcare Limited approved Q2 FY2024 financial results.
- Board Meeting Intimation for Considering And Approving The Un-Audited Financial Results For The Quarter And Half Year Ended September 30, 2024. 6 Nov
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
17 Oct - Certificate under Regulation 74(5) of SEBI submitted.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Products & Services offered:
a) Pharma Packaging:[1]
Pharma Packaging is available in two broad categories viz., Polymer based Packaging Films and Aluminum based Packaging Foils. Their sub-categories are:
Blister Films
Blister Foils
Lidding Foils
CR Foils
Laminates
b) Global Clinical Supplies and Services:[2]
Company handles domestic and global manufacturing of IMPs and Placebos, Primary
and secondary packaging with various blinding techniques, IWRS, Storage at variable temperatures.